INFLARX NV (IFRX) Stock News

NASDAQ:IFRX - Nasdaq - NL0012661870 - Common Stock - Currency: USD

0.8629 +0.04 (+4.3%)

After market: 0.8629 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IFRX Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Zacks Investment Research - Mentions: MGTX

InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

11 days ago - By: InflaRx N.V.

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

11 days ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

18 days ago - By: InflaRx N.V.

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

24 days ago - By: Yahoo Finance

InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected

a month ago - By: InflaRx N.V.

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

3 months ago - By: Benzinga - Mentions: XPER EMR BLZE ERII ...

Earnings Scheduled For May 7, 2025

6 months ago - By: ACCESS Newswire

Infinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform Finance

3 months ago - By: InflaRx N.V.

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

3 months ago - By: InflaRx N.V.

InflaRx to Participate in Upcoming Investor Conferences

3 months ago - By: InflaRx N.V.

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Zacks Investment Research - Mentions: ALGS

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: InflaRx N.V.

InflaRx to Report First Quarter 2025 Results on May 7, 2025

5 months ago - By: Yahoo Finance - Mentions: NI CVAC NU JMIA ...

NiSource Inc. (NI): Jim Cramer Says He Likes This Utility Dividend Stock

5 months ago - By: Yahoo Finance - Mentions: KRC CVAC COMP TSLA ...

Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?

5 months ago - By: InflaRx N.V.

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

5 months ago - By: InflaRx N.V.

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

6 months ago - By: InflaRx N.V.

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

6 months ago - By: InflaRx N.V.

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

6 months ago - By: InflaRx N.V.

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

6 months ago - By: InflaRx N.V.

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

6 months ago - By: InflaRx N.V.

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

7 months ago - By: InflaRx N.V.

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference